Consumer Perceptions of Health Claims in Vape Shops

消费者对电子烟商店健康声明的看法

• 批准号: 9440627
• 负责人: Kimberly G. Wagoner
• 金额: $ 11.63万
• 依托单位: WAKE FOREST UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-21 至 2019-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9440627
• 关键词: Address; Adult; Advertisements; Advertising; Age; Categories; Collection; Confusion; Data; Data Collection; Decision Making; Devices; Drug Evaluation; Electronic Nicotine Delivery Systems; Environment; Evaluation; Evaluation Research; Family Smoking Prevention and Tobacco Control Act; Funding; Future; Grant; Health; Health system; Image; Imaging technology; Knowledge; Label; Laws; Literature; Marketing; Measures; Methodology; Methods; North Carolina; Online Systems; Participant; Perception; Pilot Projects; Printed Media; Process; Product Labeling; Public Health; Research; Research Personnel; Research Priority; Risk; Safety; Sampling; Series; Surveys; Television; Testing; Therapeutic; Time; Tobacco; United States Food and Drug Administration; United States National Institutes of Health; Virginia; Weight maintenance regimen; Work; authority; falls; smoking cessation; tobacco advertising; tobacco regulatory science; vaping

PROJECT SUMMARY/ABSTRACT In May 2016, the Food and Drug Administration (FDA) issued a Final Rule, bringing electronic nicotine delivery systems (ENDS) and other products that meet a statutory definition of a tobacco product under its authority. Federal law explicitly prohibits five categories of labelling and advertising for tobacco products including: (1) false and/or misleading; (2) FDA-approved or FDA-endorsed, without FDA approval; and (3) modified risk tobacco product, without FDA approval. Additionally, ENDS cannot be marketed as a product for (4) smoking cessation or for (5) other therapeutic purposes, without prior approval from the FDA's Center for Drug Evaluation and Research (CDER). Although these types of ENDS claims have been documented online and in print media, it can be difficult to identify prohibited claims as they are often implicit. The FDA has been tasked with considering consumer perceptions of such claims when determining if they are prohibited; however, there is a significant gap in the literature regarding consumer perceptions of health claims. Additionally, no research has been conducted on advertising claims made in vape shops, which are the fastest growing segment of ENDS retailers. This study will build upon a pilot grant that developed the methodology to photographically document ENDS claims in vape shops using wearable imaging technology. In the proposed study, we will use this methodology to conduct an additional wave of data collection to document claims in vape shops. The claims from both the pilot and the new wave of data collection will be combined to create a comprehensive list of unsubstantiated claims for use in a survey, which will investigate consumer perceptions of them. It will be the first of its kind to assess how consumers interpret these real-world ENDS health claims made by retailers. At the conclusion of this study, we will have developed robust methodologies for capturing claims in the ENDS retail environment; expanded the knowledge of the types of ENDS claims being made to consumers; and developed measures for assessing consumer perceptions of those claims, all of which will aid the FDA in making determinations of whether such claims fall into one of their prohibited categories. This focused project, led by a New Investigator working with a nationally recognized team of collaborators, will lay the groundwork for future, larger studies that will increase the body of evidence regarding ENDS and directly inform the process in which the FDA identifies and classifies prohibited advertising claims.

项目摘要/摘要 2016年5月，食品药品监督管理局（FDA）发布了最终规则，带来了电子 尼古丁输送系统（末端）和其他符合法定定义的产品 烟草产品的授权。联邦法律明确禁止五类标签 以及烟草产品的广告：（1）错误和/或误导； （2）FDA批准或 未经FDA批准的FDA认可； （3）未经FDA的修改风险烟草产品 赞同。此外，末端不能作为（4）戒烟或用于的产品销售 （5）未经FDA毒品中心事先批准的其他治疗目的 评估与研究（CDER）。尽管这些类型的目的主张已经 在线和印刷媒体中记录的，可能很难确定违禁索赔 通常是隐性的。 FDA的任务是考虑消费者对此类索赔的看法 确定是否禁止它们；但是，文献存在很大的差距 关于消费者对健康索赔的看法。此外，没有进行研究 关于在vape商店中提出的广告主张，这是增长最快的目的部分 零售商。这项研究将以试点赠款为基础，该试点赠款开发了 使用可穿戴成像技术在vape商店中终止索赔。在 拟议的研究，我们将使用此方法进行额外的数据浪潮 收集以记录vape商店中的索赔。飞行员和新浪潮的主张 将合并数据收集的数据，以创建一份全面的未经证实索赔列表 在调查中使用，该调查将调查消费者对它们的看法。这将是同类的第一个 评估消费者如何解释这些现实世界的结束零售商提出的健康主张。在 这项研究的结论是，我们将开发出可靠的方法来捕获主张 在末端零售环境；扩展了对目的类型的知识 给消费者；并制定了评估消费者对那些人的看法的措施 索赔，所有这些都将有助于FDA确定此类索赔是否属于 他们禁止的类别之一。这个专注的项目，由一名新调查员领导 全国认可的合作者团队将为未来，更大的研究奠定基础 将增加有关目的的证据，并直接告知 FDA确定并分类了禁止的广告索赔。